No Data
No Data
Theratechnologies: Strong Q2 Performance and Positive Outlook Justify Buy Rating
JonesTrading Maintains Theratechnologies(THTX.US) With Buy Rating, Maintains Target Price $3
JonesTrading analyst Justin Walsh maintains $Theratechnologies(THTX.US)$ with a buy rating, and maintains the target price at $3.According to TipRanks data, the analyst has a success rate of 36.2%
Earnings Call Summary | Theratechnologies(THTX.US) Q2 2024 Earnings Conference
The following is a summary of the Theratechnologies Inc. (THTX) Q2 2024 Earnings Call Transcript:Financial Performance:Theratechnologies reported second quarter revenue at $22 million, a 25% year-
Theratechnologies Inc. (THTX) Q2 2024 Earnings Call Transcript
Theratechnologies Inc. (THTX) Q2 2024 Earnings Call Transcript
Theratechnologies | 6-K: Report of foreign private issuer (related to financial reporting)
Theratechnologies Swings to Q2 Profit as Revenue Rises 25%; Confirms FY24 Guidance
Theratechnologies (TH.TO), which commercializes two medicines that are part of HIV treatments, on Wednesday reported a swing to net income for the second quarter as revenue rose.The pharmaceutical